Zhang et al. used the internal porous structure of mesoporous silica nanoparticles (MSNs) to efficiently load bevacizumab, a VEGF antibody drug, and coupled cancer endothelial marker 1 (CEM1) monoclonal antibody on the surface of MSNs via a coupling reaction between the carboxyl group and the amide moiety in the antibody to achieve the tumor vascular targeting ability. Here, VEGFA is linked to neoplasm.